Why the study?
Does the 6-minute walk test objectively assess disease progression and fatigability over 6 months in individuals with RYR1-related myopathies?
Population
Individuals with RYR1-related myopathies (RYR1-RM)
Design
Cohort
Follow-up
6 months
Authors
Loading...
Novel RYR1-RM mechanisms identified; leaves open targeted therapies for this rare neuromuscular disease.
Does the 6-minute walk test objectively assess disease progression and fatigability over 6 months in individuals with RYR1-related myopathies?
The 6-minute walk test demonstrates disease stability over 6 months but reveals significant fatigability, suggesting its utility as an endpoint in therapeutic trials for RYR1-related myopathies.
Witherspoon et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: